Cargando…
Lenalidomide Consolidation Added to Rituximab Maintenance Therapy in Patients Remaining PET Positive After Treatment for Relapsed Follicular Lymphoma: A Phase 2 Australasian Leukaemia & Lymphoma Group NHL26 Study
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9946407/ https://www.ncbi.nlm.nih.gov/pubmed/36844180 http://dx.doi.org/10.1097/HS9.0000000000000836 |
| _version_ | 1784892331434967040 |
|---|---|
| author | Trotman, Judith Presgrave, Peter Carradice, Duncan P. Lenton, Douglas Stuart Gandhi, Maher K. Cochrane, Tara Badoux, Xavier Carlson, Julia Nkhoma, Gloria Butcher, Belinda Nikpour, Armin Fulham, Michael Johnston, Anna M. |
| author_facet | Trotman, Judith Presgrave, Peter Carradice, Duncan P. Lenton, Douglas Stuart Gandhi, Maher K. Cochrane, Tara Badoux, Xavier Carlson, Julia Nkhoma, Gloria Butcher, Belinda Nikpour, Armin Fulham, Michael Johnston, Anna M. |
| author_sort | Trotman, Judith |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9946407 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-99464072023-02-23 Lenalidomide Consolidation Added to Rituximab Maintenance Therapy in Patients Remaining PET Positive After Treatment for Relapsed Follicular Lymphoma: A Phase 2 Australasian Leukaemia & Lymphoma Group NHL26 Study Trotman, Judith Presgrave, Peter Carradice, Duncan P. Lenton, Douglas Stuart Gandhi, Maher K. Cochrane, Tara Badoux, Xavier Carlson, Julia Nkhoma, Gloria Butcher, Belinda Nikpour, Armin Fulham, Michael Johnston, Anna M. Hemasphere Letter Lippincott Williams & Wilkins 2023-02-21 /pmc/articles/PMC9946407/ /pubmed/36844180 http://dx.doi.org/10.1097/HS9.0000000000000836 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
| spellingShingle | Letter Trotman, Judith Presgrave, Peter Carradice, Duncan P. Lenton, Douglas Stuart Gandhi, Maher K. Cochrane, Tara Badoux, Xavier Carlson, Julia Nkhoma, Gloria Butcher, Belinda Nikpour, Armin Fulham, Michael Johnston, Anna M. Lenalidomide Consolidation Added to Rituximab Maintenance Therapy in Patients Remaining PET Positive After Treatment for Relapsed Follicular Lymphoma: A Phase 2 Australasian Leukaemia & Lymphoma Group NHL26 Study |
| title | Lenalidomide Consolidation Added to Rituximab Maintenance Therapy in Patients Remaining PET Positive After Treatment for Relapsed Follicular Lymphoma: A Phase 2 Australasian Leukaemia & Lymphoma Group NHL26 Study |
| title_full | Lenalidomide Consolidation Added to Rituximab Maintenance Therapy in Patients Remaining PET Positive After Treatment for Relapsed Follicular Lymphoma: A Phase 2 Australasian Leukaemia & Lymphoma Group NHL26 Study |
| title_fullStr | Lenalidomide Consolidation Added to Rituximab Maintenance Therapy in Patients Remaining PET Positive After Treatment for Relapsed Follicular Lymphoma: A Phase 2 Australasian Leukaemia & Lymphoma Group NHL26 Study |
| title_full_unstemmed | Lenalidomide Consolidation Added to Rituximab Maintenance Therapy in Patients Remaining PET Positive After Treatment for Relapsed Follicular Lymphoma: A Phase 2 Australasian Leukaemia & Lymphoma Group NHL26 Study |
| title_short | Lenalidomide Consolidation Added to Rituximab Maintenance Therapy in Patients Remaining PET Positive After Treatment for Relapsed Follicular Lymphoma: A Phase 2 Australasian Leukaemia & Lymphoma Group NHL26 Study |
| title_sort | lenalidomide consolidation added to rituximab maintenance therapy in patients remaining pet positive after treatment for relapsed follicular lymphoma: a phase 2 australasian leukaemia & lymphoma group nhl26 study |
| topic | Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9946407/ https://www.ncbi.nlm.nih.gov/pubmed/36844180 http://dx.doi.org/10.1097/HS9.0000000000000836 |
| work_keys_str_mv | AT trotmanjudith lenalidomideconsolidationaddedtorituximabmaintenancetherapyinpatientsremainingpetpositiveaftertreatmentforrelapsedfollicularlymphomaaphase2australasianleukaemialymphomagroupnhl26study AT presgravepeter lenalidomideconsolidationaddedtorituximabmaintenancetherapyinpatientsremainingpetpositiveaftertreatmentforrelapsedfollicularlymphomaaphase2australasianleukaemialymphomagroupnhl26study AT carradiceduncanp lenalidomideconsolidationaddedtorituximabmaintenancetherapyinpatientsremainingpetpositiveaftertreatmentforrelapsedfollicularlymphomaaphase2australasianleukaemialymphomagroupnhl26study AT lentondouglasstuart lenalidomideconsolidationaddedtorituximabmaintenancetherapyinpatientsremainingpetpositiveaftertreatmentforrelapsedfollicularlymphomaaphase2australasianleukaemialymphomagroupnhl26study AT gandhimaherk lenalidomideconsolidationaddedtorituximabmaintenancetherapyinpatientsremainingpetpositiveaftertreatmentforrelapsedfollicularlymphomaaphase2australasianleukaemialymphomagroupnhl26study AT cochranetara lenalidomideconsolidationaddedtorituximabmaintenancetherapyinpatientsremainingpetpositiveaftertreatmentforrelapsedfollicularlymphomaaphase2australasianleukaemialymphomagroupnhl26study AT badouxxavier lenalidomideconsolidationaddedtorituximabmaintenancetherapyinpatientsremainingpetpositiveaftertreatmentforrelapsedfollicularlymphomaaphase2australasianleukaemialymphomagroupnhl26study AT carlsonjulia lenalidomideconsolidationaddedtorituximabmaintenancetherapyinpatientsremainingpetpositiveaftertreatmentforrelapsedfollicularlymphomaaphase2australasianleukaemialymphomagroupnhl26study AT nkhomagloria lenalidomideconsolidationaddedtorituximabmaintenancetherapyinpatientsremainingpetpositiveaftertreatmentforrelapsedfollicularlymphomaaphase2australasianleukaemialymphomagroupnhl26study AT butcherbelinda lenalidomideconsolidationaddedtorituximabmaintenancetherapyinpatientsremainingpetpositiveaftertreatmentforrelapsedfollicularlymphomaaphase2australasianleukaemialymphomagroupnhl26study AT nikpourarmin lenalidomideconsolidationaddedtorituximabmaintenancetherapyinpatientsremainingpetpositiveaftertreatmentforrelapsedfollicularlymphomaaphase2australasianleukaemialymphomagroupnhl26study AT fulhammichael lenalidomideconsolidationaddedtorituximabmaintenancetherapyinpatientsremainingpetpositiveaftertreatmentforrelapsedfollicularlymphomaaphase2australasianleukaemialymphomagroupnhl26study AT johnstonannam lenalidomideconsolidationaddedtorituximabmaintenancetherapyinpatientsremainingpetpositiveaftertreatmentforrelapsedfollicularlymphomaaphase2australasianleukaemialymphomagroupnhl26study |